B+
Bull case
30%
Probability
Target price
$44.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
VCEL
VericelCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$29.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+57.6
Score
AI commentary
Primary-source tone is constructive because the May 7, 2026 earnings release showed a beat-and-raise profile with strong burn-care growth and steady margin guidance [#8-K-2026-05-07]. However, market reaction was softer than the release tone: VCEL traded at $33.47 on May 8, 2026 versus the May 7, 2026 anchor close of $35.13, a decline of about 4.7%. With low coverage and no clearly confirmed analyst revision wave yet, sentiment is best framed as cautious post-earnings monitoring rather than immediate thesis confirmation.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-08catalystQ1 beat-and-raise needs price confirmationHigh impact
Vericel reported Q1 2026 revenue up 30% to $68.4M, burn care revenue up 91% to $12.0M, adjusted EBITDA up 195% to $9.6M, and raised full-year revenue guidance to $326M-$336M from $316M-$326M while reaffirming margin targets [#8-K-2026-05-07]. The key near-term question is whether stronger MACI and burn-care demand can outweigh the stock's negative day-after reaction.
2026-08-06eventUK MACI submission remains a dated regulatory milestoneHigh impact
Management said it remains on track to submit the MACI marketing authorization application to the U.K. MHRA in 2026 [#8-K-2026-05-07]. A visible regulatory filing would extend the growth narrative beyond the current U.S. knee franchise.
2027-04-01catalystBARDA-backed NexoBrid expansion can add funded burn-care optionalityHigh impact
Vericel disclosed a ten-year BARDA contract valued at up to $197M, including a $35M base period with about $10M over the next 12 months for initial procurement, vendor-managed inventory, and development work tied to potential blast-trauma use and manufacturing initiatives [#PR-2026-04-02]. This supports longer-duration burn-care growth, but funding timing and execution remain important qualifiers.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology